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Abstract
Pancreatic ductal adenocarcinoma is characterized by a strong immunosuppressive network with a dense infiltration of 
myeloid cells including myeloid-derived suppressor cells (MDSC). Two distinct populations of MDSC have been defined: 
polymorphonuclear MDSC (PMN-MDSC) and monocytic MDSC (M-MDSC). Several factors influence the development 
and function of MDSC including the transcription factor interferon regulatory factor 4 (IRF4). Here, we show that IRF4 
deficiency accelerates tumor growth and reduces survival, accompanied with a dense tumor infiltration with PMN-MDSC 
and reduced numbers of  CD8+ T cells. As IRF4 has been described to modulate myeloid cell development and function, 
particularly of PMN-MDSC, we analyzed its role using MDSC-specific IRF4 knockout mice with the Ly6G or LysM knock-
in allele expressing Cre recombinase and Irf4flox. In GM-CSF-driven bone marrow cultures, IRF4 deficiency increased the 
frequency of MDSC-like cells with a strong T cell suppressive capacity. Myeloid (LysM)-specific depletion of IRF4 led 
to increased tumor weight and a moderate splenic M-MDSC expansion in tumor-bearing mice. PMN cell (Ly6G)-specific 
depletion of IRF4, however, did not influence tumor progression or MDSC accumulation in vivo in accordance with our 
finding that IRF4 is not expressed in PMN-MDSC. This study demonstrates a critical role of IRF4 in the generation of an 
immunosuppressive tumor microenvironment in pancreatic cancer, which is independent of IRF4 expression in PMN-MDSC.
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Introduction
The tumor microenvironment (TME) contains a variety of 
immune cells with opposing functions. While anti-tumoral 
cells such as cytotoxic T cells, T helper cells and natural 
killer cells are important in the immune surveillance and 
protection against tumors, certain immune modulatory cells 
including myeloid subsets shape the TME during immune 
equilibrium and escape phase [1] and enhance tumor pro-
gression by dampening the effector cells [2]. Three main 
subsets within the myeloid compartment are characterized 
by a strong T cell suppressive capacity. Depending on the 
cell of origin and marker expression, they can be classi-
fied in (1) monocytic myeloid-derived suppressor cells 
(M-MDSC), (2) polymorphonuclear myeloid-derived sup-
pressor cells (PMN-MDSC) and (3) tumor-associated mac-
rophages (TAM) [3, 4]. Under pathological activation such 
as chronic inflammation or cancer MDSC are expanded and 
gain a suppressive phenotype [5]. Increased numbers of 
MDSC are a negative prognostic factor for the survival of 
patients with pancreatic cancer (PDAC) [6, 7]. In addition, 
a MDSC-enriched TME is a negative predictive marker for 
the response to immunotherapy in a mouse model of PDAC 
[8]. Despite their high clinical relevance, MDSC-targeted 
treatment approaches are still insufficient [9] and there is 
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great need for a better understanding of MDSC development 
and activation in cancer [10].
Both MDSC subsets develop from the granulocyte mac-
rophage precursor (GMP) in the bone marrow, and several 
transcription factors are associated with development and 
function of MDSC [11]. Signal transducer and activator of 
transcription 3 (STAT3) has been shown to regulate MDSC 
expansion by mediating myeloid-specific growth factor 
signaling [12] as well as the suppressive activity by induc-
ing Arginase 1 (ARG1) expression, which suppresses T cell 
activity by degrading the essential amino acid arginine [13]. 
Expression of arginase is one key suppressive mechanism 
of MDSC.[3]. CCAAT/enhancer-binding protein beta (C/
EBPβ) regulates the development of polymorphonuclear 
cells under inflammatory conditions and has been also 
associated with PMN-MDSC development [14]. The tran-
scription factor interferon regulatory factor 8 (IRF8) plays 
a central role in the development of monocytic and poly-
morphonuclear cells from GMP [15]. IRF8-deficient mice 
show leukemic-like symptoms with a dense accumulation 
of polymorphonuclear cells [16]. In the context of cancer, 
strong accumulation of PMN-MDSC has been reported for 
IRF8-deficient mice [17].
Another transcription factor of the IRF family, IRF4 is 
known for its function in lymphoid cells. There, IRF4 regu-
lates antibody class switching in B cells [18, 19] and facili-
tates the differentiation of naïve  CD4+ T cells into T helper 
cell subsets such as Th2, Th9 or Th17 [20]; in  CD8+ T cells, 
IRF4 plays a crucial role in maintaining effector function 
[21, 22]. Besides its importance in the lymphoid lineage, 
IRF4 expression has been shown to regulate similar biologi-
cal functions as observed for IRF8 in myeloid cells. IRF4 is 
expressed in myeloid-precursor cells and shifts the myeloid 
development from neutrophil to monocyte development, but 
to a lesser extent than IRF8 [23]. In contrast to early myeloid 
cell development, IRF4 and IRF8 play opposing roles in 
the development of conventional dendritic cells (cDC) that 
develop from GMP via pre-cDC precursor cells. While IRF4 
is one of the lineage-defining transcription factors in the dif-
ferentiation of cDC2, IRF8 is pivotal for the differentiation 
of cDC1 [24, 25]. Recently, it has been shown that differ-
entiation of  Ly6C+ monocytes to monocytic DC (moDC) 
requires IRF4 [26]. Moreover, IRF4 expression is induced by 
cytokines mediating M2 alternatively activated macrophage 
polarization such as IL-4 and IL-13 [27], and itself regulates 
M2 polarization by inducing M2 effector genes like Arg1 
[28]. A recent publication indicates that IRF4 may regulate 
the differentiation and suppressive function of MDSC [29].
In this study, we aim at understanding the role of IRF4 
in MDSC development and function in a murine model of 
PDAC which is characterized by strong expansion of MDSC 
[30, 31], by using mice with either global, myeloid cell- or 
granulocyte-specific Irf4 deletion.
Results
Systemic IRF4 deficiency accelerates PDAC tumor 
growth and expands MDSC in vivo
To study the role of IRF4 in pancreatic cancer we made 
use of a transplantable, orthotopic tumor model using the 
tumor cell line T110299, which originate from a genetically 
engineered, spontaneous mouse model with PDAC-charac-
teristic driver mutations (KrasG12D Tp53R172H). We recently 
reported that this model is particularly enriched for myeloid 
cells such as MDSC [31]. Three weeks after orthotopic 
tumor induction, tumor weight of Irf4−/− mice was signifi-
cantly increased compared to IRF4 sufficient Irf4flox/flox con-
trols (Fig. 1a, b). Moreover, the survival of tumor-bearing 
Irf4−/− mice was significantly reduced (Fig. 1c). We noted 
no significant differences in histologic tumor morphology 
between both genotypes (Fig. S1). T110299 tumors from 
both control and Irf4−/− mice showed a moderately differ-
entiated tubular to tubulo-papillary adenocarcinoma pattern 
with similar amounts of desmoplastic stroma and moderate 
chronic inflammatory infiltrates, resembling human pancre-
atic ductal adenocarcinoma. To study the immunological 
consequences of IRF4 deficiency, immune cell frequency 
of T110299 tumor-bearing mice was analyzed three weeks 
after tumor induction by flow cytometry. In the spleen of 
Irf4−/− mice, PMN-MDSC, M-MDSC and  CD4+ T cell fre-
quencies were significantly increased, whereas the frequency 
of  CD8+ T cells was reduced (Fig. 1d). In the TME, PMN-
MDSC frequency was significantly increased in Irf4−/− mice, 
whereas the frequency of  CD8+ T cells was dramatically 
reduced, indicating a profound immunosuppressive TME in 
mice deficient for IRF4 (Fig. 1e) that may account for the 
more rapid tumor progression in these mice.
Low IRF4 expression in PDAC patients is associated 
with reduced one‑year survival
To confirm these findings in the human disease, the effect 
of IRF4 expression on the survival of metastasized PDAC 
patients was analyzed using the Cancer Genome Atlas 
(TCGA) data set. Metastasized PDAC patients were cate-
gorized based on their IRF4 expression level in two groups 
(upper and lower quartile) and survival of these selected 
groups was analyzed. The median survival of patients with 
low IRF4 expression was 15.9 months versus 18.7 months 
of patients with high expression levels. There was no sig-
nificant difference in the overall survival in regard to the 
IRF4 expression (Fig. 1f). However, χ2-test of survival after 
1 year revealed a significantly reduced survival of patients 
with lower IRF4 expression (χ2 = 5.33, p = 0.02) (Fig. 1g).
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IRF4 is expressed in M‑MDSC, but not PMN‑MDSC
To better understand the role of IRF4 in the initiation of the 
immunosuppressive and myeloid cell-enriched TME, IRF4 
expression of both monocytic and polymorphonuclear cells 
in tumor-free and T110299 tumor-bearing mice was ana-
lyzed by flow cytometry. IRF4 was expressed homogenously 
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Fig. 1  IRF4 deficiency accelerates PDAC tumor growth and expan-
sion of MDSC populations in blood and spleen. a–e T110299 tumors 
were induced orthotopically in Irf4−/− and wild-type (WT) mice. 
After 21 days, tumor weight was measured (b). Kaplan–Meier curve 
depicts survival of orthotopic PDAC-bearing mice (c). Immune cell 
frequencies in spleen (d) and tumor (e) were analyzed by flow cytom-
etry. Differences between genotypes were statically analyzed using 
the Mann–Whitney U test (b, d, e) or Log rank test (c). a–e Pooled 
data from 2–3 independent experiments are shown, error bars rep-
resent mean ± SEM (n = 3–8 mice/group). e IRF4 expression level 
of metastasized PDAC patients and Kaplan–Meier survival curve of 
patients from the upper and lower quartile of IRF4 expression is dis-
played for 36 months. Median survival of both groups in months is 
indicated with dotted lines (f). Contingency table of patients based 
on their survival status after one year and IRF4 expression level (g). 
Asterisks indicate *p < 0.05, **p < 0.01, ***p < 0.001
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independent of the tumor status. In contrast, IRF4 expression 
in polymorphonuclear cells in blood, spleen and tumor was 
absent (Fig. 2a, b).
As this is in contrast to published data [29], we further 
validated this finding by alternative approaches and used 
conditional myeloid-specific IRF4 knockout mouse models. 
Irf4flox mice have been designed to express green fluorescent 
protein (GFP) instead of IRF4 upon successful Cre-mediated 
recombination under the same physiological control as IRF4 
[18]. Therefore, the conditional IRF4 knockout mice can also 
act as reporter mice. LysMCreIrf4fl/fl mice have an IRF4 dele-
tion in polymorphonuclear cells, monocytes, macrophages 
and partly dendritic cells [32], whereas Ly6GCreIrf4fl/fl mice 
have the IRF4 deletion in polymorphonuclear cells only [33].
In line with our previous observation, M-MDSC of the 
LysMCreIrf4fl/fl mice were positive for GFP in the blood, 
spleen and tumor. No GFP expression was detectable in 
PMN-MDSC or M-MDSC of the Ly6GCreIrf4fl/fl mice. In 
contrast, in LysMCreIrf4fl/fl mice, a small fraction of approxi-
mately 15% of  GFP+ PMN-MDSC was detectable in blood, 
spleen and tumor (Fig. 2c). As the GFP expression in those 
PMN-MDSC may derive from its precursor cell express-
ing LysM, we characterized GFP expression of GMP in 
LysMCreIrf4fl/fl mice. Indeed, 12% of GMP expressed GFP 
indicating that IRF4 is expressed early in the myeloid cell 
development (Fig. 2d). To further characterize the cell-
specific expression pattern of IRF4 in myeloid cells, bone 
marrow cells were stimulated overnight with the known 
IRF4 inducers IL-4 and IL-13. As expected,  CD11b+ 
 CD11c+ MHC-II+ bone marrow-derived dendritic cells 
(BMDC) responded to cytokine stimulation by upregulat-
ing IRF4 expression. IRF4 expression was only inducible 
in  CD11b+Ly6ChighLy6G− M-MDSC-like cells, but not in 
 CD11b+Ly6CintLy6G+ PMN-MDSC-like cells (Fig. 2e). 
Taken together, the data demonstrate that IRF4 is expressed 
in M-MDSC and myeloid precursor cells but is absent in 
mature Ly6G-expressing PMN-MDSC.
IRF4 deficiency expands suppressive MDSC‑like cells 
in vitro
GM-CSF-driven bone marrow cultures are an established 
model to study MDSC in vitro [14]. To evaluate the role 
of IRF4 in the development and function of MDSC, 
bone marrow cells of wild-type and Irf4−/− mice were 
cultured for seven days in the presence of GM-CSF, and 
cell composition was analyzed. The frequency of MDSC-
like  (Gr1+MHC-IIlow) cells was significantly increased 
in bone marrow cultures from Irf4−/− mice, while both 
MHC-IIint and MHC-IIhigh BMDC were significantly 
reduced (Fig. 3a, b). Next, T cell suppressive capacity 
of bone marrow-derived MDSC was measured in T cell 
co-cultures in the presence of anti-CD3/anti-CD28 beads. 
T cell proliferation was measured and revealed that IRF4-
deficient bone marrow culture cells suppressed the prolif-
eration of both  CD4+ and  CD8+ T cells more potently, as 
compared to wild-type controls (Fig. 3c). However, as the 
difference in MDSC composition may influence the over-
all suppressive activity, FACS-sorted  Gr1highMHC-IIlow 
MDSC-like cells from wild-type and Irf4−/− mice were 
individually analyzed in a T cell suppression assay. Sorted 
 Gr1+ MDSC-like cells of wild-type and Irf4−/− mice 
exhibited similar T cell suppressive capacities, arguing 
against a direct role of IRF4 in controlling the suppressive 
capacity of MDSC-like cells (Fig. 3d).
Myeloid‑specific deletion of IRF4 accelerates PDAC 
growth and expands M‑MDSC numbers
The two conditional IRF4 knockout mouse models 
described above were used to study the intrinsic role of 
IRF4 in myeloid cells in  vivo. KPC-derived T110299 
tumors were orthotopically induced in Ly6GCreIrf4fl/fl 
mice, LysMCreIrf4fl/fl mice as well as Irf4fl/fl control mice 
(Fig. 4a). While there was no significant difference in 
tumor growth between Ly6GCreIrf4fl/fl and control mice, 
tumor weight was significantly increased in LysMCreIrf4fl/fl 
mice, as compared to Irf4fl/fl control mice (Fig. 4b). Flow 
cytometric analysis of MDSC frequencies three weeks 
after tumor induction showed no difference in PMN-
MDSC frequency in blood, spleen and tumor of LysM-
CreIrf4fl/fl mice and Ly6GCreIrf4fl/fl mice compared to Irf4fl/fl 
controls; however, M-MDSC frequency was moderately 
increased in the spleen of LysMCreIrf4fl/fl mice (Fig. 4c). 
Compared to Irf4fl/fl controls, there was no significant 
difference in  CD4+ or  CD8+ T cell frequencies in LysM-
CreIrf4fl/fl mice or Ly6GCreIrf4fl/fl mice (Fig. 4d). Of note, 
both myeloid-specific IRF4-deficiencies had no influence 
on the survival of PDAC-bearing mice (Fig. 4e).
In conclusion, this study demonstrates that only early 
myeloid precursor cells and M-MDSC express IRF4, 
whereas mature PMN-MDSC lack IRF4 expression. In 
our hands, specific deletion of IRF4 in PMN-MDSC has 
no influence on PMN-MDSC expansion, their T cell sup-
pressive capacity, tumor growth or survival. In contrast, 
myeloid cell-specific deletion of IRF4 in LysMCreIrf4fl/fl 
mice slightly accelerates tumor growth, which was accom-
panied by increased M-MDSC frequency in the spleen. 
No impact on PMN-MDSC numbers or survival is seen 
in these mice. These findings argue against a pro-tumoral 
effect of IRF4 in PMN-MDSC. Hence, as observed in mice 
with global IRF4 deficiency, the IRF4-mediated effects in 
other immune cells likely account for the immunosuppres-
sive TME with its dense MDSC infiltration.


















































































































































































































































Fig. 2  IRF4 is expressed in monocytic but not polymorphonuclear 
cells. a–d KPC-derived T110299 tumors were induced orthotopi-
cally. a, b IRF4 expression of MDSC subsets from tumor-free and 
PDAC-bearing wild-type mice was analyzed by flow cytometry. a A 
representative histogram of anti-IRF4 staining as well as isotype con-
trol staining from a PDAC-bearing mouse is depicted. After 21 days, 
GFP expression of MDSC (c) and GMP (d) subsets of Ly6GCreIrf4fl/fl 
(green), LysMCreIrf4fl/fl (blue) and Irf4fl/fl (black) mice was determined 
by FACS analysis. e IRF4 expression of myeloid cells from bone 
marrow cultures were analyzed by flow cytometry in the absence and 
presence of IL-4 and IL-13. The difference between stimulated and 
unstimulated cells was statistically analyzed using unpaired student’s 
t-test. Error bars represent mean ± SEM (n = 2–5 mice/group), aster-
isks indicate *p < 0.05, **p < 0.01
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Discussion
In this study, we show that global IRF4 deficiency accel-
erates tumor growth, increases frequencies of tumor-
infiltrating PMN-MDSC and reduces survival in a murine 
PDAC model. This is in line with human TCGA cohort 
data showing that the one-year survival of metastasized 
PDAC patients with low IRF4 expression is significantly 
reduced. Reporter mice for studying IRF4 expression in 
myeloid cells in vivo revealed the induction of IRF4 in 
myeloid precursor cells and M-MDSC, but not in PMN-
MDSC. Accordingly, IRF4 deletion in  Ly6G+ cells had no 
influence on MDSC frequency, the suppressive function, 
tumor growth or survival. In contrast, IRF4 deletion in 
 LysM+ cells increased tumor weight and led to moderately 
expanded M-MDSC population in the spleen; yet there was 
no impact on survival.
A recent study reported that IRF4 is expressed by PMN-
MDSC as well as M-MDSC and that 4T1 breast tumors 
reduced the expression of IRF4 in both cell types. Further-
more, the study demonstrated by knock-down and overex-
pression experiments in bone marrow cultures showed that 
lower IRF4 expression increased the frequency of PMN-
MDSC and was associated with higher suppressive activ-
ity of MDSC. A myeloid cell-specific knockout of IRF4 
increased the tumor weight in B16F10 tumor bearing mice 
[29]. In contrast to this report, we clearly demonstrate by 
the use of reporter mice as well as antibody staining that in 
our PDAC model IRF4 expression is limited to M-MDSC, 
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Fig. 3  IRF4 deficiency leads to MDSC-like cell expansion in bone 
marrow cultures in  vitro. a–d Bone marrow cells from WT and 
Irf4−/− mice were cultured for seven days in the presence of GM-
CSF. a, b Cell composition of bone marrow cultures was measured. 
c Bone marrow cells from WT and IRF4-deficient mice were co-
cultured with CFSE-labeled T cells and proportion of proliferated 
 CFSElow  CD8+ and  CD4+ T cells was analyzed by flow cytometry. d 
Gr1high MHC-IIlow cell population of WT and IRF4-deficient bone 
marrow cultures were FACSorted, co-cultured with CFSE-labeled T 
cells and the proportion of proliferated  CFSElow  CD8+ and  CD4+  was 
determined. The difference between genotypes was statistically ana-
lyzed using Mann–Whitney U test, error bars represent mean ± SEM 
(n = 3), asterisks indicate *p < 0.05 and ***p < 0.001





















































































































































































































































































































































































































































Fig. 4  Targeted deletion of IRF4 in LysMCre but not Ly6GCre 
mice increases tumor growth without influencing survival. a–d 
KPC-derived T110299 tumors were induced orthotopically in 
Ly6GCreIrf4fl/fl (green), LysMCreIrf4fl/fl (blue) and Irf4fl/fl (black) mice. 
After 21 days, a, b tumor weight was measured and c MDSC as well 
as d T cell frequency was analyzed by flow cytometry. e Survival 
of PDAC-bearing mice was monitored. Statistical analysis was per-
formed using Kruskal Wallis test, followed by Dunn’s multiple com-
parison test between controls and conditional knockout mice. Pooled 
data from three independent experiments are depicted, error bars rep-
resent mean ± SEM (n = 8–14 mice/group), p value of Dunn’s test are 
shown in the graph, asterisks indicate *p < 0.05 and **p < 0.01
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4T1 cell line was generated from a BALB/c mouse and the 
PDAC model we used originated from a C57BL/6 mouse, 
it remains open whether this discrepancy is due to different 
tumor models or mouse strains used.
A fraction of GMP was found to express IRF4, which is 
why they likely contain precursors for both M-MDSC and 
PMN-MDSC. In line with this finding, a small proportion 
of PMN-MDSC exhibited a weak GFP expression in LysM-
CreIrf4flox reporter mice. Taking together, the findings argue 
that IRF4 is expressed in some precursors of granulocytes, 
but is lost during PMN-MDSC differentiation. Considering 
our data and the current literature of IRF4 and IRF8 data on 
early myeloid cell development, IRF4 and IRF8 have seem-
ingly overlapping functions in myeloid cell development. 
The data also suggest that IRF8 may compensate for IRF4 
function in IRF4-deficient animals [23]; however, the exact 
molecular mechanism of how IRF4-regulates cell fate deci-
sion remains elusive.
The suppressive function of MDSC has been linked to 
their immature state [34]. The GM-CSF-driven bone mar-
row culture system is frequently used to study dendritic cells 
and MDSC in vitro [14, 29]. IRF4-deficiency shifts the bone 
marrow culture from mature dendritic cells towards imma-
ture MDSC-like cells. This shift in the population frequency 
questions again earlier findings showing that induction of 
IRF4 decreases and inhibition of IRF4 increases the sup-
pressive capacity of MDSC intrinsically [29]. Using sorted 
MDSC-like cells from these cultures as well as genetic dele-
tion instead of siRNA knock-down, we demonstrate that the 
intrinsic suppressive activity is not directly influenced by 
IRF4.
Given the result that IRF4 is not expressed in polymor-
phonuclear cells, it was not surprising that the deletion of 
IRF4 in  Ly6G+ cells in vivo did not influence tumor growth, 
overall survival or MDSC cell frequency. In line with the 
previous report [29], myeloid-specific deletion of IRF4 
using the LysMCreIrf4fl/fl mice, accelerated tumor growth, 
but had no influence on the overall survival. The frequency 
of M-MDSC was moderately elevated in the spleen, but not 
in tumors, suggesting that IRF4 rather impacts monocyte 
differentiation or proliferation.
Besides the minor effects of myeloid-specific deletion of 
IRF4, the accelerated tumor growth in global IRF4-deficient 
mice demonstrates a central role of IRF4 in shaping the TME 
and anti-tumor immunity. IRF4 has been described to be piv-
otal for efficient antigen cross-presentation of moDC [26] 
and to be required for sustained  CD8+ T cell activation [21, 
22]. Given the substantial reduction of intratumoral  CD8+ 
T cells, it seems more likely that this is due to an impaired 
sustained activation of antitumoral T cells than due to the 
amplification and action of MDSC in IRF4-deficent mice. 
We recently demonstrated that in the PDAC model used the 
PMN-MDSC frequency correlates with tumor weight [31]. 
One can therefore argue that the elevated levels of PMN-
MDSC in the global IRF4 deficient mouse could be a sec-
ondary effect of the increased tumor size.
In summary, we demonstrate that IRF4 plays an important 
role in shaping the immune cell composition in the TME of 
murine pancreatic cancer. Due to the increased PMN- and 
M-MDSC frequency in IRF4 knockout mice, we hypoth-
esized that a MDSC-intrinsic role of IRF4 might explain 
the effect on tumor progression. However, polymorphonu-
clear cells do not express IRF4 in tumor bearing mice and 
in line with that, the deletion of IRF4 in  Ly6G+ cells did 
not alter tumor development. Despite some effects of IRF4 
deletion in  LysM+ cells on tumor growth, again, no effect on 
survival or PMN-MDSC accumulation was observed. Our 
results, therefore, suggest that the observed in vivo effects 
in globally IRF4-deficient mice are secondary and due to 
globally imbalanced immune regulation, but not due to an 
IRF4-intrinsic effect in MDSC.
Material and methods
Mice
C57BL/6 wild-type mice were purchased from Jan-
vier, France. Irf4flox mice (B6.129S1-Irf4tm1Rdf/J) were 
a kind gift from Prof. Bopp (Institute of Immunology, 
Universitätsmedizin Mainz), Ly6GCre mice (C57BL/6-
Ly6g(tm2621(Cre−tdTomato)Arte)) were a kind gift from Prof. 
Gunzer (Institute for Experimental Immunology and 
Imaging, University of Duisburg-Essen), LysMCre mice 
(B6.129P2-Lyz2tm1(cre)Ifo/J) were a kind gift from PD Dr. 
Lech (Institute of Clinical Biochemistry, Klinikum der Uni-
versität München). FLP1 recombinase expressing FLPe 
mice (B6;SJL-Tg(ACTFLPe)9205Dym)/J) were purchased from 
Jackson Laboratory (Sulzfeld, Germany). All mice were 
kept on C57BL/6 background with a 12-h light/dark cycle, 
water ad lib. and regular chow diet (sniff, Soest, Germany) at 
the Klinikum der Universität München, Munich, Germany. 
Experiments were performed according to national ethical 
guidelines approved by the local government (Regierung 
von Oberbayern, Munich, Germany; file number 55.2-1-54-
2532-175-12). LysMCre were cross-bred with Irf4flox mice 
to obtain LysMCreIrf4flox, and Ly6GCre were cross-bred with 
Irf4flox mice to obtain Ly6GCreIrf4flox. Both mouse strains 
were kept on homozygous Irf4fl/fl background. Exons 1 and 
2 of Irf4 in B6.129S1-Irf4tm1Rdf/J mice are flanked by two 
FRT sites. To generate global IRF4-deficient mice, B6;SJL-
Tg(ACTFLPe)9205Dym/J mice were cross-bred with B6.129S1-
Irf4tm1Rdf/J mice and, as described before, Irf4−/− mice were 
obtained [18]. IRF4 sufficient mice originating from those 
breedings were used as littermate controls. Genotypes of all 
mice were routinely analyzed by PCR.
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DNA isolation and genotyping
DNA from ear or tail biopsies was extracted and analyzed 
as described before [35]. Briefly, biopsies were incubated in 
75 µl alkaline lysis buffer (25 mM NaOH, 0.2 mM EDTA in 
 H2O) for 30 min at 95 °C and reaction was stopped by add-
ing 75 µl neutralization buffer (40 mM Tris-HCl in  H2O). 
Supernatant containing genomic DNA was subsequently 
used for genotyping with locus specific primer pairs listed 
in supplementary table 1 by using genotype-specific cycling 
programs, as summarized in supplementary table 2.
Cell culture
Primary cells were cultured in RPMI-1640 medium (Sigma-
Aldrich, Taufkirchen, Germany), supplemented with 10% 
fetal calf serum (FCS), 2 mM l-glutamine, 100 U/l penicil-
lin, 0.1 mg/ml streptomycin, 100 mM non-essential amino 
acids (all gibco®, Thermo Fisher Scientific, Karlsruhe, 
Germany), 1 mM sodium pyruvate and 50 mM 2-mercap-
toethanol (both Sigma Aldrich). T110299 tumor cells had 
been isolated from tumors of genetically-engineered Ptf1a-
Cre KrasG12D p53fl/R172H (KPC) mice and kindly provided 
by Prof. Siveke (West German Cancer Center (WTZ), Uni-
versity Hospital Essen). T110299 cells were cultured in 
DMEM high glucose media (Sigma-Aldrich), supplemented 
with 10% FCS, 2 mM l -glutamine, 100 U/l penicillin and 
0.1 mg/ml streptomycin (all gibco®). All cells were kept 
in a humidified incubator at 37 °C and 5%  CO2 and were 
regularly tested for mycoplasma contamination.
Bone marrow culture
Bone marrow cells were isolated by flushing femur and tibia. 
2 × 106 cells per 10 ml were seeded in a 10 cm cell cul-
ture round plate in primary cell medium supplemented with 
20 ng/ml GM-CSF (Peprotech, London, United Kingdom). 
After three days, 10 ml primary cell medium supplemented 
with 20 ng/ml GM-CSF was added. Five days after cell iso-
lation, 66% of the medium containing 20 ng/ml GM-CSF 
was exchanged. If indicated, cells were stimulated overnight 
with 10 ng/ml IL-4 and 10 ng/ml IL-13 (both Peprotech, 
London, United Kingdom).
Orthotopic tumor induction
Orthotopic tumors were induced by surgical implantation, 
as described before [36]. Briefly, 6–12 weeks old mice were 
anesthetized, and by surgical incision of the skin and peri-
toneum, the pancreas was carefully mobilized. After the 
injection of 2 × 105 T110299 cells in 25 µl PBS, the pan-
creas was relocated, and the incision was closed by surgical 
suture. Mice were monitored daily and distressed mice were 
sacrificed. Tumor weight of sacrificed animals was measured 
and normalized to average tumor weight of WT animals in 
the respective experiment.
Cell isolation
Spleens and tumors were isolated from the mice and blood 
was drawn. Spleens were processed through a 70 µm cell 
strainer. Erythrocytes from spleen and blood were removed 
using the red blood cell lysis buffer (BD Biosciences, Hei-
delberg, Germany). Tumor tissue was minced into pieces 
and mechanically dissociated using the mouse Tumor Dis-
sociation Kit with the gentleMACS™ Dissociator applica-
tion (both Miltenyi Biotech, Bergisch Gladbach, Germany), 
according to the manufacturer´s instructions. The cell sus-
pension was separated from tissue debris by sequentially 
using 100 µm and 70 µm cell strainers. For functional assays, 
untouched T cells were isolated using the Pan T cell isolation 
Kit II, and for MDSC isolation the Myeloid-Derived Sup-
pressor Cell Kit was used (both Miltenyi Biotec). In brief, 
in a two-step separation process, PMN-MDSC  (CD11b+ 
 Ly6Cint  Ly6G+) were isolated with anti-Ly6G beads fol-
lowed by M-MDSC  (CD11b+  Ly6Chigh  Ly6G−) isolation 
using anti-Gr1 beads. The purity of isolated cells was > 95% 
for T cells and between 75 and 90% for MDSC.
Cells from bone morrow cultures were isolated by FAC-
Sorting. Cells were stained as described for FACS analysis. 
 FVDnegGr1highMHC-IIlow and  FVDnegGr1lowMHC-IIhigh were 
sorted on a BD Aria III system (BD Bioscience, Heidelberg, 
Germany).
FACS analysis
Prior to fluorochrome staining of single cell suspensions, 
FcR III/II blocking was performed using the anti-CD16/
CD32 TrueStain fcX™ antibody (BioLegend, London, UK). 
Dead cells were stained for exclusion with fixable viability 
dye (FVD) (Thermo Fisher Scientific, Karlsruhe, Germany). 
For cell-specific surface staining, cells were labeled with 
CD4 (clone GK1.5), CD8 (clone 53–6.7), CD11b (clone 
M1/70), CD11c (clone N418), CD45 (clone 30-F11), Gr1 
(clone RB6-8C5), Ly6C (clone HK1.4), Ly6G (clone 1A8), 
MHC-II (clone AF6-120.1; all BioLegend, London, UK). 
IRF4 (clone IRF4.3E4; BioLegend, London UK) or isotype 
control (clone RTK2071; both BioLegend, London, UK) 
were stained intracellularly using the one-step intracellular 
staining protocol of the eBioscience™ FoxP3/Transcrip-
tion Factor Staining Buffer Kit (Thermo Fisher Scientific, 
Karlsruhe, Germany). Samples were acquired on a BD LSR-
Fortessa system (BD Bioscience, Heidelberg, Germany), and 
data were analyzed with FlowJo X software (FLOWJO LLC, 
Ashland, OR, USA).
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T cell suppression assay
Isolated T cells were stained with 2.5 µM Carboxyfluores-
cein succinimidyl ester (CFSE; Thermo Fisher Scientific) 
in PBS for 4 min at room temperature and reaction was 
stopped with FCS. For the assessment of MDSC suppressive 
capacity, MDSC were co-cultured with anti-CD3/anti-CD28 
stimulated CFSE-labeled T cells. For this, 5 × 104 T cells 
(per well) were seeded into 96-well plates and cocultured 
with 0.31 × 104, 0.63 × 104, 1.25 × 104, 2.5 × 104 or 5 × 104 
MDSC. Each well was supplemented with 1 µl beads (Dyna-
beads™ Mouse T-Activator CD3/CD28, gibco®, Thermo 
Fisher Scientific, Karlsruhe, Germany). After 72 h, CFSE 
dilution of  CD4+ and  CD8+ T cells was analyzed by flow 
cytometry (BD Canto II system, BD Bioscience, Heidelberg, 
Germany). Unstimulated CFSE-labeled T cells only were 
used to set the threshold of proliferated T cells  (CFSElow).
Human dataset analysis
Survival data, IRF4 expression level as well as information 
on metastasis status of PDAC patients from the TCGA cohort 
were retrieved via the Xena browser [37]. Two groups of 
patients with metastasized PDAC were analyzed: Patients with 
low IRF4 expression level (≤ the lower quartile) and patients 
with high IRF4 expression level (≥ the upper quartile). The 
survival of these two groups was analyzed in a Kaplan–Meier 
analysis and compared with a Wilcoxon test. The survival 
status after one year was displayed in a contingency table. As 
all expected cell frequencies were above five, χ2 test was used 
to compare one-year survival of the two groups. All analysis 
on the TCGA data set was performed using IBM® SPSS® 
Statistics 25. Graphs were generated in Graphpad Prism 8.3.
Histology
Tumors were embedded in Tissue-Tek® O.C.T.™ (Sakura 
Finetek GmbH, Staufen, Germany), rapidly frozen in liquid 
nitrogen and stored at − 80 °C. Prior to analysis, samples 
were thawed, once washed in PBS, fixed in  ROTI®Histofix 4% 
paraformaldehyde (Roth, Karlsruhe, Germany) and subjected 
to automated routine histological tissue processing. After par-
affin embedding, four µm thick whole tissue sections were 
stained using haematoxylin-eosine (HE) staining (haema-
toxylin: Waldeck, Münster, Germany; eosine: Sigma) in an 
automated tissue stainer (Tissue Tek Prisma, Sakura Finetek).
Statistical analysis
Data represent individual mice and are displayed as mean 
with standard error of the mean (SEM). To test for statisti-
cally significant differences between two groups, student’s 
t test (for expression data only) or Mann–Whitney U test 
was used. To compare more than two groups, we applied 
Kruskal–Wallis test followed by Dunn’s multiple com-
parison post hoc tests between selected samples. To ana-
lyze differences in the survival, Mantel–Cox Logrank test 
was conducted. For the statistical analysis of suppression 
assays, only the difference between the conditions with 
the highest concentration of MDSC was analyzed using a 
Mann–Whitney U test. Statistical analysis of murine data 
was performed in Graphpad Prism 8.3.
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